12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AD/PNP-FaraAMP: Phase I ongoing

PNP completed the first 3 cohorts of an open-label, U.S. Phase I trial evaluating AD/PNP-FaraAMP in about 15 patients with solid tumors, primarily head and neck tumors. The company said there were no major toxicities and that...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >